**FOI Ref: 6184**

**Category(ies): Clinical - Drugs**

**Subject: Usage of biologic and biosimilar products within Rheumatology**

**Date Received: 13/01/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Analysing the usage of biologic and biosimilar products within Rheumatology.  It would be really helpful if you could answer the following two questions:  |
| Q1. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:* Abatacept [Orencia]
* Adalimumab [Humira]
* Adalimumab Biosimilars
* Apremilast [Otezla]
* Baricitinib [Olumiant]
* Certolizumab [Cimzia]
* Etanercept [Enbrel]
* Etanercept Biosimilars
* Filgotinib [Jyseleca]
* Golimumab [Simponi]
* Guselkumab [Tremfya]
* Infliximab [Remicade]
* Infliximab Biosimilars
* Ixekizumab [Taltz]
* Risankizumab [Skyrizi]
* Rituximab [MabThera]
* Rituximab Biosimilars
* Sarilumab [Kevzara]
* Secukinumab [Cosentyx]
* Tocilizumab [Ro Actemra]
* Tofacitinib [Xeljanz]
* Upadacitinib [Rinvoq]
* Ustekinumab [Stelara]
 | * 30
* 0
* 113
* 0
* 35
* 0
* 6
* 238
* 0
* 9
* 0
* 0
* 15
* 0
* 0
* 0
* 9
* 0
* 16
* 39
* 3
* 1
* 3
 |
| Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs. * Adalimumab [Humira]
* Adalimumab Biosimilars
* Certolizumab [Cimzia]
* Etanercept [Enbrel]
* Etanercept Biosimilars
* Golimumab [Simponi]
* Infliximab [Remicade]
* Infliximab Biosimilars
* Ixekizumab [Taltz]
* Secukinumab [Cosentyx]
* Upadacitinib [Rinvoq]
 | No patients currently meet the criteria of been treated with a medicine in the list where the primary diagnosis was either M479 (Spondyloarthrosis) or M45 (Ankylosing Spondylitis).As December coding may not be complete yet this figure could change for December. |